Published July 15, 2026
A Law Set to Outlaw a $28 Billion Industry Still Doesn’t Define Its Most Important Word
We’ve written a lot about November 12 — the day the federal hemp redefinition takes effect and, by industry estimates, wipes out roughly 95% of the hemp cannabinoid market. Every countdown article, including ours, treats that date as a hard wall.
Here’s what those countdowns mostly leave out: the wall has a hole in it, and the agency responsible for patching it is now five months past a legal deadline to do so.
When Congress passed the hemp ban inside last November’s spending bill, it didn’t just set a date. It also handed the FDA a homework assignment — publish the technical definitions that make the ban actually enforceable — and gave the agency 90 days to finish. That deadline was February 10, 2026. It came and went. As of this writing in July, the FDA still hasn’t delivered. The ban is a machine missing several of its own parts, and nobody outside a few trade publications is talking about it.
The Homework the FDA Didn’t Turn In
Section 781 of the appropriations act — the provision that rewrites what “hemp” means — gave the FDA four specific tasks, due within 90 days of enactment.
Three of them are lists. The agency was required to publish a catalog of every cannabinoid capable of being naturally produced by the cannabis plant; a list of every THC-class cannabinoid naturally occurring in the plant; and a list of all other cannabinoids that have — or are marketed to have — effects similar to THC. Together, these lists are supposed to tell the entire industry exactly which compounds are legal and which are contraband after November 12.
The fourth task is the one that matters most, and it’s a single word: container.
The 0.4-milligram cap at the heart of the ban is measured “per container.” The statute offers a starting definition — the innermost wrapping or vessel in direct contact with the product, like a jar, bottle, bag, or cartridge — but explicitly directs the FDA to provide “additional information and specificity” about what that means in practice. Without that clarification, the central number in the entire law floats free of any fixed reference point.
None of the four have been published. The Congressional Research Service confirmed the miss in a report noting the guidance was still absent as of May 2026. Marijuana Moment says it sent the FDA multiple requests for an update and got no reply.
Why “Container” Is Worth Fighting Over
It’s easy to dismiss a definitional delay as bureaucratic trivia. It isn’t. The meaning of “container” determines who survives November.
Consider a bottle of 30 CBD softgels. Is the “container” the bottle — in which case the whole bottle must contain under 0.4mg of total THC, an almost impossibly low bar for a full-spectrum product? Or is it each individual softgel? The difference between those two readings is the difference between a compliant product and a Schedule I felony. Multiply that ambiguity across every gummy jar, tincture bottle, and multipack in the country and you can see why the industry has been begging for this one word to be pinned down.
Then there’s the detail almost no one has connected — and it may be the most consequential of all. The ban also prohibits “intermediate” hemp products: material in the middle of the manufacturing process, not yet a finished good. Here’s the problem, as cannabis analyst Deb Tharp has flagged: during extraction, CBD crude and distillate routinely exceed 0.3% total THC by weight in the tank, even when the final bottled product ends up well under the limit. On paper, that in-process material isn’t hemp anymore. Which means that unless the FDA’s “container” guidance clarifies whether processing equipment counts, a legitimate CBD maker producing a perfectly non-intoxicating final product could be holding a controlled substance in a stainless-steel tank on the way there. The definition doesn’t just decide which products are legal — it decides whether the act of making legal products is itself a federal crime.
What the Silence Actually Tells Us
Why would the FDA blow a statutory deadline on something this consequential? The honest answer is that nobody outside the agency knows — it hasn’t explained itself. But two readings are plausible, and they point in opposite directions.
The first: the task is genuinely, maybe impossibly, hard. Cataloging “all known cannabinoids with similar effects to THC” is a moving scientific target in a field where labs synthesize novel compounds faster than regulators can name them. Building a list with real legal force, that holds up when someone’s freedom depends on it, is the kind of job that resists a 90-day clock. One legal analysis read the delay as a sign the FDA is struggling with exactly this technical and political complexity.
The second reading is more strategic. The Trump administration has publicly asked Congress to amend this very ban to protect full-spectrum CBD. An agency that expects the underlying law to change has little incentive to pour months into implementing definitions that may be obsolete by November. Notably, the FDA did move on a related front — sending a CBD enforcement policy to the White House’s OMB for review in March — which suggests the inaction on the lists may be selective, not simple paralysis.
Either way, the effect on operators is the same: they’re being asked to reformulate products, rewrite labels, and make bet-the-company inventory decisions against a rulebook whose key pages are blank.
The Deadline Doesn’t Wait for the Homework
Here’s the cruel mechanical reality. The November 12 effective date is written into the statute. The FDA’s missing guidance is not a precondition for it. Nothing in the law says the ban pauses until the definitions arrive.
So the industry faces the worst of both worlds: a hard enforcement date and a soft, undefined standard. Operators who wait for clarity may get it after the deadline that clarity was supposed to inform — or never. As one compliance firm bluntly advised, the months remaining are “a planning window, not a waiting period,” and anyone expecting final FDA guidance before they have to act may be planning around a document that never comes.
This is also why the missed deadline has become ammunition in the fight to delay the ban entirely. Hemp advocates argue, with some force, that you cannot fairly enforce a prohibition whose terms the government itself hasn’t finished writing. It’s a clean argument for the Hemp Planting Predictability Act’s two-year delay — how can businesses comply with rules that don’t fully exist? Whether that argument moves a Congress that has so far ignored every delay effort is another question.
What to Watch
Three things worth tracking between now and November. First, the Federal Register — the moment those cannabinoid lists and the “container” clarification finally publish, the real compliance scramble begins in earnest, and the specifics will decide winners and losers overnight. Second, that FDA enforcement policy sitting at OMB, which may end up being the document that actually governs how aggressively any of this gets enforced. And third, whether the FDA’s own tardiness becomes the argument that finally gives a delay bill traction on Capitol Hill.
For now, the strangest fact of the hemp ban stands: a law written to bring order to an unregulated market is itself, five months and counting, missing the definitions that would make it a rule anyone can actually follow.
The clock is running. The instructions are late. And November isn’t waiting for either.
Part of our ongoing coverage of the November hemp deadline — see our full breakdown of what the ban outlaws, and follow the rest at our CBD & Hemp hub.
Sources:
Congress.gov — CRS report on the hemp definition change and FDA requirements (primary source): https://www.congress.gov/crs-product/IN12620
Marijuana Moment (original miss report + the CRS follow-up confirming still-unpublished as of May): https://www.marijuanamoment.net/congressional-researchers-call-out-fda-for-missing-deadline-to-publish-cannabinoid-list-and-define-hemp-containers/
Business of Cannabis (the intermediate-product/extraction-tank problem, Deb Tharp analysis): https://businessofcannabis.com/us-hemp-industry-in-limbo-as-fda-deadline-for-cannabinoid-definitions-arrives/
Frier Levitt (Section 781’s three changes, the statutory “container” language): https://www.frierlevitt.com/articles/federal-hemp-redefinition-2026-thc-limits-compliance/